07
2024
05

crashbandicootracingps4| Fuhong Hanlius now rises more than 5% and the international multi-center Phase III clinical trial of HLX22 has been approved in the United States

crashbandicootracingps4| Fuhong Hanlius now rises more than 5% and the international multi-center Phase III clinical trial of HLX22 has been approved in the United States

  复宏汉霖(02696)早盘上涨5crashbandicootracingps4.05%,现报17.46港元,成交额379.10万港元。

  复宏汉霖宣布,公司创新型抗HER2单抗HLX22crashbandicootracingps4的国际多中心III期的新药临床试验(IND)申请已经获得美国FDA许可,拟用于联合曲妥珠单抗及化疗一线治疗HER2阳性晚期胃癌。目前,全球尚无同类用于治疗HER2阳性胃癌的HER2双靶向疗法获批准上市。

« 上一篇 下一篇 »